Pharmacy Track: Outlook of 340B Program
Wednesday, September 15, 2021 12:00 PM - 1:00 PM
Amid lawsuits from pharmaceutical manufacturers and a new HHS administration, the 340B Program faces an uncertain future. For pharmacy leaders, the unpredictability of reimbursements impacts your ability to care for patients, your supply chain operations, and your financial outcomes. In this session, we will cut through the uncertainty and review the outlook of 340B Program, including the current status of litigation and the Biden administration’s actions to date. We’ll also offer strategies to reduce the impact of these reimbursement uncertainties.
- Analyze strategies to plan for and manage reimbursement uncertainties.
- Explain the status of litigation and its impact on pharmacy leaders.
- Outline the Biden administration’s position and actions surrounding the 340B Program.
Kenny served as the inaugural director of 340B pharmacy services, starting in 2016. He managed both compliance and optimization of the 340B program, where he and his team built the program from the ground. His role evolved to include pharmacy business and analytics, in which he supported pharmacy-related contract negotiations, pharmacy projects/initiatives, and pharmacy-driven analyses. Before assuming the director’s role, Kenny served as the assistant director of pharmacy, ambulatory services, where he had a dual role of managing an infusion center pharmacy and handling all medication management for NYULH in the ambulatory care setting to promote safety, quality and standardization. Before he stepped into pharmacy leadership, he was an oncology pharmacist at the Perlmutter Cancer Center at NYULH.
Dr. Yu received his PharmD from Rutgers University in New Jersey and his MBA with a concentration in health care from George Washington University in Washington, DC. He became a 340B Apexus Certified Expert (ACE) in 2017.